Sertran

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sertran

Quick Facts

Property Description
Active ingredient Sertraline hydrochloride (INN: Sertraline)
Form Oral tablets (e.g., film-coated tablets)
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI), Antidepressant
Common use Modulation of mood and emotional regulation
Origin Synthetic compound

What Type of Medicine is Sertran (Sertraline)?

Sertran is a prescription-only medicine and a Psychotropic medication classified pharmacologically as an Antidepressant. Its active ingredient, Sertraline, belongs specifically to the class of Selective Serotonin Reuptake Inhibitors (SSRIs). Sertraline functions as an antidepressant and is part of the first-line treatment for certain mood disorders. This means the drug is widely recognized and used to help stabilize the mental and emotional state. Sertraline is utilized across various patient groups and maintains broad clinical recognition. The categorization as an SSRI distinguishes it from older antidepressant classes by its highly focused, primary action on the serotonin system in the brain.


Composition and Origin: Is Sertran a Synthetic Compound?

The sole active ingredient in Sertran is the substance Sertraline hydrochloride, which is formulated as an oral solid dosage form, typically presented as tablets. Sertraline is defined as a synthetic compound, meaning its precise chemical structure is created through laboratory synthesis rather than being isolated directly from natural sources. This synthetic origin ensures that each single product dose delivered via the oral route contains a consistent, high-purity amount of the pharmaceutical agent, crucial for dependable therapeutic action. Other popular brands containing this same formulation include Zoloft and Lustral, affirming its globally accepted standard of composition.


What is the General Purpose of an SSRI Antidepressant?

The general purpose of this type of medication is to assist in the restoration of stable emotional balance and regulated mood, such as supporting an adult during a period of sustained low mood. Sertran achieves this by selectively preventing nerve cells from rapidly reabsorbing the neurochemical serotonin after it has been released, a process called reuptake blockade. Sertraline serves as an agent in the management of key mood disturbances. This identifies the drug’s role in helping individuals who require biochemical support to regulate their emotional health. By enhancing the functional availability of serotonin in the brain, the medication provides the foundational support needed for mood regulation.

Regulatory References

  1. MedlinePlus Drug Information: Sertraline
  2. Cochrane Review on Sertraline for Depression

What side effects are possible with Sertran?

Sertran: Possible Side Effects and Safety Information

The safety profile of Sertraline (Sertran) is formally defined by regulatory authorities based on classified adverse reactions and specific safety constraints documented in official labeling.

Frequency-Classified Adverse Reactions

The most commonly reported effects documented in official sources include those affecting the gastrointestinal and nervous systems. Nausea, diarrhea, and insomnia are often categorized as Very Common (ge 1/10). Other effects classified as Common (ge 1/100 to <1/10) include dry mouth, decreased appetite, dizziness, tremor, increased sweating, and sexual dysfunction (e.g., ejaculation failure and decreased libido) [1.4, 1.7].

System-Organ Class (SOC) Examples from Regulatory Labeling
Gastrointestinal Nausea, Diarrhea, Dry mouth
Nervous System Tremor, Dizziness, Somnolence
Psychiatric Disorders Insomnia, Agitation, Decreased libido

Serious Adverse Reactions and Safety Constraints

The official labeling includes specific warnings regarding rare but clinically significant adverse reactions. There is a documented risk for Serotonin Syndrome, a serious condition that can result from the accumulation of serotonin. The product label also notes the potential for an increased risk of Abnormal Bleeding and the Activation of Mania/Hypomania, particularly in patients with undiagnosed bipolar disorder [1.4, 2.4].

For pediatric and young adult patients (le 24 years), there is an explicit safety constraint concerning an increased risk of Suicidal Thoughts and Behaviors, particularly during the initiation of treatment or following a dosage adjustment [2.4]. Additionally, caution is advised for older adults due to a potentially increased risk of Hyponatremia (low blood sodium) [1.4]. Following prolonged use, the abrupt cessation of Sertraline may lead to symptoms associated with Discontinuation Syndrome [1.7].

Overdose and Emergency Response

Any suspected Sertran overdosage requires immediate medical attention. Regulatory authorities document that the primary clinical concerns involve severe effects on the Central Nervous System (CNS) and the cardiovascular system. Overdose manifestations may range from mild presentations to life-threatening events such as seizures and coma. Specific documented CNS signs include altered mental status, tremor, and hyperreflexia.

A severe and potentially fatal outcome is the emergence of Serotonin Syndrome, especially when Sertran is ingested alongside other proserotonergic drugs. This serious condition is officially recognized by symptoms like tachycardia, labile blood pressure, and hyperthermia. Cardiovascular toxicity is documented by the risk of QRS and QTc interval prolongation, necessitating continuous cardiac monitoring during hospital observation.

Since no specific antidote is known for Sertraline overdose, the official management approach is strictly symptomatic and supportive. This may involve procedures like gastrointestinal decontamination (e.g., using activated charcoal) and the maintenance of a patent airway. Urgent medical help must be sought for any ingestion exceeding the prescribed amount due to the documented potential for severe complications.

Therapeutic Uses of Sertran

Sertran is relevant for easing symptoms related to systemic imbalance across a range of conditions affecting mood and mental stability. It is commonly used to help with Major Depressive Disorder (MDD) and symptom clusters that interfere with daily comfort across several Anxiety Disorders.

The medication is applied in contexts where a patient experiences sustained low mood, chronic loss of interest, or the heightened fear states seen in Panic Disorder. It generally supports managing the distinct patterns of Obsessive-Compulsive Disorder (OCD) and is applied in addressing symptoms that become more disruptive during flare-ups, such as the mood swings of Premenstrual Dysphoric Disorder (PMDD). It is used in situations involving certain distressing symptoms across multiple conditions, including MDD, OCD, Panic Disorder, Post-Traumatic Stress Disorder, and Social Anxiety Disorder. This supportive therapeutic benefit generally helps patients cope more steadily with symptom fluctuations and assists with maintaining functional stability.

“This medication is applied across domains where additional symptomatic support is needed, assisting patients when symptoms become more noticeable.”


Quick Fact: Supports Management of Intrusive Thoughts

Regulatory References

  1. NIH MedlinePlus overview on Sertraline

Eligibility and Restrictions for Use

Official Eligibility and Restrictions for Sertran (Sertraline)

Official regulatory documents define strict criteria for who is eligible to use Sertran, separating the population into groups who are allowed use, those who require caution, and those for whom the medicine is absolutely contraindicated.


Absolute Contraindications

Sertran must not be used in patients who are concurrently taking, or have recently discontinued within 14 days, a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue. Concomitant use with Pimozide is also prohibited. Use is further contraindicated in individuals with known hypersensitivity to Sertraline.


Population Eligibility Status

Category Regulatory Status (Excerpted)
Adults (18+ years) Use is generally established for all approved indications.
Children (6–17 years) Use is established only for Obsessive-Compulsive Disorder (OCD). Safety for other indications is not established.
Children (<6 years) Safety and effectiveness are not established by regulatory agencies.
Hepatic Impairment Use requires caution in mild impairment. Use is not recommended in moderate to severe impairment (effects are not studied).
Pregnancy/Lactation Use in the third trimester may increase the risk of neonatal complications. Sertraline is present in breast milk; requires risk assessment.
High-Risk Conditions Requires caution in patients with a history of seizures or risk factors for QTc prolongation. Avoided in those with untreated anatomically narrow angles (glaucoma risk).

What should I know about interactions with other medicines?

Sertran Interactions with other medicines and products

Certain combinations of medicines and products are officially documented to interact with Sertran (Sertraline). Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue, are strictly contraindicated due to the documented risk of Serotonin Syndrome. A mandatory 14-day washout period is required when switching between Sertran and any MAOI. Co-administration with Pimozide is also contraindicated due to a documented increase in Pimozide plasma concentration.

Sertran is an inhibitor of the CYP2D6 enzyme, which can lead to reduced clearance and increased plasma exposure of co-administered medicines that are substrates of this enzyme. Conversely, the co-administration of Sertran with inhibitors of other enzymes, such as CYP3A4/CYP2C19, may officially increase Sertraline exposure.

Pharmacodynamic interactions involve co-administration with other serotonergic agents (e.g., Triptans, Tramadol, St. John's Wort), which elevates the documented risk of Serotonin Syndrome. Combining Sertran with Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Aspirin, or other anticoagulants/antiplatelets increases the official risk of bleeding. Regulatory documents also note that administration of the tablet formulation with food officially increases maximum plasma concentration ( C max) by 25%. In the context of specific populations, official labeling states that in patients with mild chronic hepatic impairment, Sertraline clearance is reduced, resulting in approximately 3-fold greater drug exposure.

Mechanism of Action

Primary Mechanism: Serotonin Transporter Inhibition

Sertran works by acting as a selective inhibitor of the Serotonin Transporter ( SERT) protein. The SERT is found on presynaptic nerve endings and is responsible for recycling the neurotransmitter serotonin ( 5-HT) from the synaptic space. Blocking this protein immediately increases the concentration of 5-HT available to communicate between nerve cells , modifying the activity of the serotonergic system by altering extracellular serotonin concentration.


Neurophysiological Adaptation and System Rebalancing

The sustained increase in 5-HT levels drives a slower process of neurophysiological adaptation, primarily affecting circuits within the Limbic System. This adaptation involves gradual changes, such as the desensitization of certain 5-HT receptors on nerve cell surfaces. This mechanism modulates activity within neural circuits that regulate physiological responses and affective states. These adaptations characterize the long-term physiological effect produced by the mechanism.

Dosage and Administration Information

How to Use Sertran: Official Administration Guidelines

Sertran (Sertraline) is administered exclusively via the oral route, available in both tablet form (25 mg, 50 mg, and 100 mg strengths) and as an oral concentrate solution.

Official Dosing and Frequency

The standard adult dosing schedule requires once daily intake. The initial dose is dependent on the specific indication being addressed, with a starting dose of 50 mg per day for conditions like Major Depressive Disorder (MDD), but only 25 mg per day initially for others, such as Panic Disorder (PD), before increasing after one week.

Dosing Principle Regulatory Instruction
Dose Adjustment Increases occur in 25 mg to 50 mg increments, with a minimum interval of one week between adjustments, up to a maximum of 200 mg/day.
PMDD Schedule The medication may be administered either continuously (daily) or intermittently (only during the luteal phase of the menstrual cycle).

Administration Conditions and Adjustments

Sertraline tablets can be taken with or without food. If the oral concentrate is used, it must be diluted immediately before intake with specific liquids such as water, juice, or certain sodas; it must not be mixed with other liquids.

The official labeling mandates adjustments for specific populations. Patients with mild hepatic impairment are generally prescribed a starting and maximum daily dosage that is half the typical recommended dose. For pediatric patients being treated for Obsessive-Compulsive Disorder (OCD), the initial dose is lower, starting at 25 mg/day for those aged 6–12. Upon discontinuation, the dose must be gradually reduced (tapered).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sertran (Sertraline)

This section provides an overview of the official research structure for Sertraline, describing the types of studies conducted, the populations examined, and the kinds of outcomes measured, without offering clinical advice or guarantees about individual results.


Evidence for Major Depressive Disorder (MDD)

The research base for Sertran in MDD is substantial, relying on numerous Randomized Controlled Trials (RCTs) and comprehensive meta-analyses that pool results from multiple studies. Research was conducted using controlled settings to explore how symptoms change over defined time intervals in adult outpatients experiencing periods of heightened symptom activity.

Studies monitored specific outcomes related to systemic or functional imbalance, such as quantifying changes in the severity of depressive symptoms using standardized clinical scales. Researchers also examined the rate at which patients reached symptom resolution, known as remission, and examined the time until symptom recurrence in maintenance studies.


Evidence for Obsessive-Compulsive Disorder (OCD)

Research examined Sertran for conditions characterized by functional limitations and intrusive thoughts, such as OCD. The primary evidence comes from multiple placebo-controlled RCTs conducted in both adults and the pediatric population (children aged 6 and older, and adolescents).

Studies explored changes measured in obsessive-compulsive symptom severity using specialized scales. Studies reported that the measured onset of observed symptom change was sometimes longer for OCD compared to the findings reported in MDD studies.


Evidence for Anxiety and Stress-Related Conditions

Research has examined Sertran's application across a spectrum of anxiety and stress-related conditions, including Panic Disorder (PD), Social Anxiety Disorder (SAD), and Post-Traumatic Stress Disorder (PTSD). The evidence for these uses relies primarily on placebo-controlled RCTs and includes research exploring short-term symptom changes.

Studies monitored patterns related to measured changes in symptom severity when comparing Sertran to placebo over defined time intervals. Research has also explored the durability of the outcomes over time, with follow-up studies extending up to one year or longer in patients who responded to treatment.


What Research Gaps and Uncertainty Remain

While a substantial body of evidence exists, the research highlights areas that are still uncertain. Long-term effects are not fully established, as there is limited information for outcomes extending beyond one year for many anxiety disorders. Evidence quality varies across studies, and subgroup findings are uncertain in specific patient groups, such as those with highly treatment-resistant conditions. Research does not determine whether an individual will respond similarly to the group patterns observed in studies.

Key Studies & References

  1. Sustained response versus relapse: the pharmacotherapeutic goal for obsessive-compulsive disorder
  2. Sertraline - StatPearls (NIH Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Sertran (FAQ)

Q: Is Sertran the same as other medications for similar issues?

Sertran's active ingredient, Sertraline, is classified by regulatory authorities as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification identifies its primary function, which is to affect only the serotonin system in the brain, distinguishing it from other types of medications that may target different chemical pathways.


Q: What are the main benefits people report when taking Sertran?

Clinical studies and official information indicate that the medication is monitored for its effect on systemic or functional imbalance. Researchers track outcomes such as quantifying the reduction in the severity of depressive symptoms using standardized scales and monitoring the time until symptom resolution, known as remission. This factual data forms the basis for describing the drug’s intended therapeutic effect.


Q: Can Sertran be taken with alcohol?

Official patient information advises that it is not recommended to drink alcohol while taking Sertran, based on documented risks when combined.


Q: Are there any specific foods or drinks to avoid while using Sertran?

Regulatory sources recommend avoiding grapefruit or grapefruit juice while taking Sertran. This avoidance is recommended because official reports indicate this interaction can increase the amount of Sertran in the bloodstream.


Q: Is Sertran generally suitable for older adults?

Studies have examined the use of Sertran in older patients (aged 60 and over) and have described it as a beneficial option for Major Depressive Disorder in this population. However, official labeling advises caution due to a potentially increased risk of Hyponatremia, a condition characterized by low sodium levels in the blood.


Q: Are there special considerations for children taking Sertran?

Use is established only for Obsessive-Compulsive Disorder (OCD) in children and adolescents (6–17 years); safety for other uses is not established. An explicit warning exists regarding an increased risk of Suicidal Thoughts and Behaviors for young patients. The official documentation also notes that growth checks are a consideration for children and teenagers using the drug.


Q: What happens if I forget to take a dose of Sertran?

The official patient information and administration guidelines contain specific, non-directive instructions on how to handle a missed dose, which involves strict timing rules to avoid taking two doses close together. These instructions are detailed in the 'How to Use Sertran' section of the core content.


Q: Is Sertran habit-forming or addictive?

Sertran is not classified as a controlled substance by regulatory agencies and has been documented to have little risk of abuse or addiction. However, prolonged use can result in the body developing a physical dependence, meaning abrupt cessation may lead to the symptoms associated with discontinuation syndrome.


Q: Is Sertran known to cause weight changes?

In adults, studies have suggested a small weight gain may occur with longer-term use of the medication. In pediatric patients, official reports indicate that decreased weight has been observed, possibly due to associated side effects like decreased appetite.


Q: Does Sertran affect blood pressure?

Changes in blood pressure (both high and low) have been reported in the safety information based on clinical trial data and postmarketing surveillance.


Q: Does Sertran interact with herbal supplements?

Official documentation advises caution regarding co-administration with other serotonergic agents, which includes the herbal supplement St. John's Wort. The combination with such supplements elevates the documented risk of Serotonin Syndrome.


Q: What happens if Sertran is taken alongside medications that cause sedation?

Official warnings note that combining Sertran with other medications that cause drowsiness or sedation may lead to increased drowsiness or impaired cognitive ability.


Q: How do I know if Sertran is working for me?

Based on pharmacokinetic data, steady-state plasma levels are achieved after approximately one week of consistent, once-daily dosing. In clinical studies, researchers monitored measurable effects by tracking changes in symptom severity using standardized rating scales, but individual patient response time may vary.


Q: Is it necessary to avoid grapefruit while taking Sertran?

Regulatory sources advise the avoidance of grapefruit or grapefruit juice. The official reason is that this interaction can increase the blood levels of Sertran, which may lead to a higher risk of experiencing side effects.


Q: Does Sertran cause vivid dreams or nightmares?

Vivid or strange dreams have been reported as a documented side effect associated with the use of Sertran. This is included in the established safety profile documented in official information.


Q: Why do some people need a higher or lower dose of Sertran?

Official regulatory dosing schedules indicate that differences in prescribed dosage are based on several factors. These include the specific condition being addressed (e.g., OCD versus Panic Disorder), the patient's age (e.g., children versus adults), and the presence of underlying health issues such as mild hepatic impairment.


Q: What research is currently being done on Sertran?

Regulatory and government-funded organizations often register or publish protocols for ongoing clinical research into the use of Sertran. Examples include studies examining its potential use for various conditions, such as recent research protocols exploring its application following traumatic brain injury (TBI).

How should Sertran be stored and disposed of?

Official Storage and Disposal Instructions

The storage and disposal of Sertraline (Sertran) must adhere strictly to the conditions specified in regulatory documents to ensure stability and safety.

Requirement Area Official Rule
Temperature & Protection Store at controlled room temperature, typically 59 F to 86 F (15 C to 30 C). Do not freeze and protect the product from moisture.
Container & Handling Keep the medication in its original container and ensure the bottle is tightly closed. Oral concentrate requires immediate dilution before use.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.
Disposal Disposal should primarily utilize drug take-back programs. If unavailable, the FDA advises mixing the product with an unappealing substance (e.g., used coffee grounds) and disposing of the mixture in household trash. Do not dispose of the medication into wastewater.

Regulatory authorities require these measures for temperature control, moisture protection, and container integrity, which define the product's stability profile. Disposal must follow authorized methods to protect public health and the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sertran found in:

A-Z Index: